Your browser doesn't support javascript.
loading
Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China.
Guo, Zihao; Zeng, Ting; Lu, Yaoqin; Sun, Shengzhi; Liang, Xiao; Ran, Jinjun; Wu, Yushan; Chong, Marc K C; Wang, Kai; Zhao, Shi.
Afiliação
  • Guo Z; JC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China.
  • Zeng T; School of Public Health, Xinjiang Medical University, Urumqi, China.
  • Lu Y; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Department of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, China.
  • Sun S; School of Public Health, Xinjiang Medical University, Urumqi, China.
  • Liang X; Urumqi Center for Disease Control and Prevention, Urumqi, China.
  • Ran J; Department of Epidemiology and Biostatistics, School of Public Health, Capital Medical University, Beijing, China.
  • Wu Y; Department of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong, China.
  • Chong MKC; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Wang K; JC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China.
  • Zhao S; Centre for Health Systems and Policy Research, Chinese University of Hong Kong, Hong Kong, China.
Commun Med (Lond) ; 4(1): 92, 2024 May 18.
Article em En | MEDLINE | ID: mdl-38762678
ABSTRACT

BACKGROUND:

As SARS-CoV-2 Omicron variants circulating globally since 2022, assessing the transmission characteristics, and the protection of vaccines against emerging Omicron variants among children and adolescents are needed for guiding the control and vaccination policies.

METHODS:

We conducted a retrospective cohort study for SARS-CoV-2 infections and close contacts aged <18 years from an outbreak seeded by Omicron BA.5 variants. The secondary attack rate (SAR) was calculated and the protective effects of two doses of inactivated vaccine (mainly Sinopharm /BBIBP-CorV) within a year versus one dose or two doses above a year after vaccination against the transmission and infection of Omicron BA.5 were estimated.

RESULTS:

A total of 3442 all-age close contacts of 122 confirmed SARS-CoV-2 infections aged 0-17 years were included. The SAR was higher in the household setting and for individuals who received a one-dose inactivated vaccine or those who received a two-dose for more than one year, with estimates of 28.5% (95% credible interval [CrI] 21.1, 37.7) and 55.3% (95% CrI 24.4, 84.8), respectively. The second dose of inactivated vaccine conferred substantial protection against all infection and transmission of Omicron BA.5 variants within a year.

CONCLUSIONS:

Our findings support the rollout of the second dose of inactivated vaccine for children and adolescents during the Omciron BA.5 predominant epidemic phase. Given the continuous emergence of SARS-CoV-2 variants, monitoring the transmission risk and corresponding vaccine effectiveness against SARS-CoV-2 variants among children and adolescents is important to inform control strategy.
Children and adolescents have reported suffering less severe outcomes from the SARS-CoV-2 Omicron variant. However, the risk of transmission and vaccine effectiveness among this population group is not well studied. Here, we used contact tracing data that was collected during an Omicron BA.5 outbreak from Urumqi, China, before the exit of "zero-COVID" measures, to evaluate the spread of SARS-CoV-2 infection among those age under 18 years, and the effectiveness of inactivated vaccine regimens. Our findings indicate there is a high rate of transmission among children and adolescents in a household setting and receiving two doses of inactivated COVID-19 vaccination within a year was more effective than a single dose or two doses given more than a year apart. These findings highlight the importance of tracking transmission and vaccine effectiveness of novel SARS-CoV-2 variants in younger populations to inform control strategies.

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Commun Med (Lond) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Commun Med (Lond) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China